Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms with Sibutramine Pharmacokinetics in Healthy Korean Subjects

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 5, 2009, Pages 511-518

  Kim, K A ^a   Song, W K ^a   Park, J Y ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; SIBUTRAMINE;

AREA UNDER THE CURVE; ARTICLE; ASSOCIATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; METABOLITE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL;

ADULT; APPETITE DEPRESSANTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOBUTANES; CYTOCHROME P-450 CYP3A; GENOTYPE; HUMANS; KOREA; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 70350216031     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.145     Document Type: Article

References (50)

1. Nisoli, E. & Carruba, M.O. An assessment of the safety and efcacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes. Rev. 1, 127-139 (2000).
2. Heal, D.J., Aspley, S., Prow, M.R., Jackson, H.C., Martin, K.F. & Cheetham, S.C. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to diferentiate it from d-amphetamine and d-fenfuramine. Int. J. Obes. Relat. Metab. Disord. 22 (suppl. 1),S18-28; discussion S29 (1998).
3. Luque, C.A. & Rey, J.A. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann. Pharmacother. 33, 968-978 (1999).
4. Hind, I.D., Mangham, J.E., Ghani, S.P., Haddock, R.E., Garratt, C.J. & Jones, R.W. Sibutramine pharmacokinetics in young and elderly healthy subjects. Eur. J. Clin. Pharmacol. 54, 847-849 (1999).
5. Stock, M.J. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int. J. Obes. Relat. Metab. Disord. 21 (suppl. 1),S25-S29 (1997).
6. Luscombe, G.P., Hopcroft, R.H., Thomas, P.C. & Buckett, W.R. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 28, 129-134 (1989).
7. Reductil [package insert] Abbott Park, IL: Abbott Laboratories, 2000.
8. Bae, S.K. et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab. Dispos. 36, 1679-1688 (2008).
9. Ingelman-Sundberg, M., Sim, S.C., Gomez, A. & Rodriguez-Antona, C. Infuence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007).
10. Kim, K.A. et al. Efect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin. Pharmacol. Ther. 80, 646-656 (2006).
11. Park, J.Y. et al. Efect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin. Pharmacol. Ther. 79, 590-599 (2006).
12. Kim, K.A., Park, P.W., Hong, S.J. & Park, J.Y. The efect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 84, 236-242 (2008).
13. Kim, K.A., Park, P.W. & Park, J.Y. Efect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet efect of clopidogrel in healthy subjects. Eur. J. Clin. Pharmacol. 64, 589-597 (2008).
14. Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25, 193-200 (2004).
15. Kirchheiner, J. & Seeringer, A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta 1770, 489-494 (2007).
16. Narkiewicz, K. Sibutramine and its cardiovascular profle. Int. J. Obes. Relat. Metab. Disord. 26 (suppl. 4),S38-S41 (2002).
17. Haller, C. Dieting agents and regimens. In Toxicologic Emergencies 8th edn. (eds. Flomenbaum, N.E., Goldfrank, L.R., Hofman, R.S., Howland, M.A., Lewin, N.A. & Nelson, L.S.) 620-629 (McGraw-Hill Professional, New York, 2006).
18. The Health Research Group. Petition to FDA to ban the diet drug sibutramine (MERIDIA) (HRG publication 1613). In Protecting Health, Safety, and Democracy (2002).
19. Yim, K.M., Ng, H.W., Chan, C.K., Yip, G. & Lau, F.L. Sibutramine-induced acute myocardial infarction in a young lady. Clin. Toxicol. (Phila). 46, 877-879 (2008).
20. Wooltorton, E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 166, 1307-1308 (2002).
21. Ernest, D., Gershenzon, A., Corallo, C.E. & Nagappan, R. Sibutramine-associated QT interval prolongation and cardiac arrest. Ann. Pharmacother. 42, 1514-1517 (2008).
22. Harrison-Woolrych, M., Clark, D.W., Hill, G.R., Rees, M.I. & Skinner, J.R. QT interval prolongation associated with sibutramine treatment. Br. J. Clin. Pharmacol. 61, 464-469 (2006).
23. Hiratsuka, M. et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol. 58, 417-421 (2002).
24. Kimura, M., Ieiri, I., Mamiya, K., Urae, A. & Higuchi, S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug. Monit. 20, 243-247 (1998).
25. Desta, Z., Soukhova, N.V. & Flockhart, D.A. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother. 45, 382-392 (2001).
26. Kim, K.A. et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin. Pharmacol. Ther. 72, 90-99 (2002).
27. Kirchheiner, J. et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13, 619-626 (2003).
28. Ekhart, C., Doodeman, V.D., Rodenhuis, S., Smits, P.H., Beijnen, J.H. & Huitema, A.D. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) afect the pharmacokinetics of thiotepa and tepa. Br. J. Clin. Pharmacol. 67, 50-60 (2009).
29. Saitoh, A. et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J. Acquir. Immune Defc. Syndr. 45, 280-285 (2007). (Pubitemid 47012374)
30. Kim, K.A., Park, P.W., Lee, O.J., Kang, D.K. & Park, J.Y. Efect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 47, 87-93 (2007).
31. Kim, K.A., Park, P.W. & Park, J.Y. Efect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Chirality 21, 485-491 (2009).
32. Gonzalez, H.M. et al. CYP2C19-and CYP3A4-dependent omeprazole metabolism in West Mexicans. J. Clin. Pharmacol. 43, 1211-1215 (2003).
33. Desta, Z., Zhao, X., Shin, J.G. & Flockhart, D.A. Clinical signifcance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913-958 (2002).
34. Kim, K.A., Chung, J., Jung, D.H. & Park, J.Y. Identifcation of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur. J. Clin. Pharmacol. 60, 575-581 (2004).
35. Venkatakrishnan, K., von Moltke, L.L., Court, M.H., Harmatz, J.S., Crespi, C.L. & Greenblatt, D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28, 1493-1504 (2000).
36. Störmer, E., von Moltke, L.L. & Greenblatt, D.J. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J. Pharmacol. Exp. Ther. 295, 793-801 (2000).
37. Hinson, J.L., Leone, M.B., Leese, P.T., Moult, J.T., Carter, F.J. & Faulkner, R.D. Steady-state interaction study of sibutramine (Meridia™) and erythromycin in uncomplicated obese subjects. Pharm. Res. 13, S116 (1996).
38. Hinson, J.L., Leone, M.B., Leese, P.T., Moult, J.T., Carter, F.J. & Faulkner, R.D. Steady-state interaction study of sibutramine (Meridia™) and ketoconazole in uncomplicated obese subjects. Pharm. Res. 13, S116 (1996).
39. Sharma, B. & Henderson, D.C. Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin. Pharmacother. 9, 2161-2173 (2008).
40. Florentin, M., Liberopoulos, E.N. & Elisaf, M.S. Sibutramine- associated adverse efects: a practical guide for its safe use. Obes. Rev. 9, 378-387 (2008).
41. Lenzer, J. FDA is incapable of protecting US "against another Vioxx". BMJ 329, 1253 (2004).
42. Eroglu, E., Gemici, G., Bayrak, F.002C Kalkan, A.K. & Degertekin, M. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use. Int. J. Cardiol. (2008).
43. Gaciong, Z. & Placha, G. Efcacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. J. Hum. Hypertens. 19, 737-743 (2005).
44. Kim, K.S., Kim, E.J., Lee, H.A. & Park, S.J. Efect of sibutramine HCl on cardiac hERG K(+) channel. Mol. Cell. Biochem. 320, 125-131 (2009).
45. May, D.G., Porter, J., Wilkinson, G.R. & Branch, R.A. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin. Pharmacol. Ther. 55, 492-500 (1994).
46. Xie, H.G., Huang, S.L., Xu, Z.H., Xiao, Z.S., He, N. & Zhou, H.H. Evidence for the efect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 7, 115-119 (1997).
47. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee: CYP3A4 allele nomenclature. http://www.cypalleles.ki.se/ cyp3a4.htm Accessed 26 February 2009.
48. Park, J.Y., Kim, K.A., Park, P.W., Suh, K.H. & Lee, G.S. Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study. Clin. Ther. 26, 2092-2101 (2004).
49. Rohrbacher, M., Kirchhof, A., Geisslinger, G. & Lötsch, J. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics 7, 995-1002 (2006).
50. Kim, K.A., Song, W.K., Kim, K.R. & Park, J.Y. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J. Clin. Pharm. Ther. (in press).